Thioredoxin prevents thioacetamide-induced acute hepatitis by Okuyama, Hiroaki et al.
BioMed  Central
Page 1 of 2
(page number not for citation purposes)
Comparative Hepatology
Open Access Proceedings
Thioredoxin prevents thioacetamide-induced acute hepatitis
Hiroaki Okuyama*1, Yasuyuki Shimahara1, Hajime Nakamura2, 
Shinichi Araya2, Norifumi Kawada3, Yoshio Yamaoka3 and Junji Yodoi2
Address: 1Department of Gastroenterological Surgery, Graduate School of Medicine, Kyoto University, Japan, 2Department of Biological 
Responses, Laboratory of Infection and Prevention, Institute for Virus Research, Kyoto University; Shogoin, Kawahara-cho, Sakyo-ku, Kyoto, Japan 
606-8397 and 3Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan
Email: Hiroaki Okuyama* - hokuyama@yf7.so-net.ne.jp; Yasuyuki Shimahara - shima-kyt@umin.u-tokyo.ac.jp; 
Hajime Nakamura - hnakamur@kuhp.kyoto-u.ac.jp; Shinichi Araya - saraya@virus.kyoto-u.ac.jp; Norifumi Kawada - kawadanori@med.osaka-
cu.ac.jp; Yoshio Yamaoka - yy@kuhp.kyoto-u.ac.jp; Junji Yodoi - yodoi@virus1.virus.kyoto-u.ac.jp
* Corresponding author    
Introduction
Thioredoxin (Trx) is an endogenous multifunctional pro-
tein with a redox-active disulfide/dithiol within the con-
served active site sequence: -Cys-Gly-Pro-Cys- [1]. Trx is
also a stress-inducible protein whose expression is
enhanced by various types of stresses, e.g., viral infection,
exposure to UV light, x-ray irradiation, and hydrogen per-
oxide (H2O2) [2]. Furthermore, Trx is a scavenger of reac-
tive oxygen species (ROS), and recombinant Trx has
protective activity against ROS-mediated cytotoxicity [3].
We have previously reported that Trx attenuates an
ischemic brain damage by scavenging radicals [4].
Based on these considerations, we hypothesized that Trx
could attenuate oxidants-mediated acute hepatitis. TAA is
known to be a hepatotoxin via generation of free radicals,
resulting in ROS-mediated acute hepatitis. In the present
study, we subjected wild type (Wt) mice and Trx trans-
genic (Tg) mice to TAA-induced acute lethal hepatitis. Our
findings shed light on the protective role of Trx for acute
liver injury.
Methods
TAA-induced Acute Lethal Hepatitis
Male mice weighing 25–30 g were used for in vivo liver
injury models. We injected TAA (100 µg/g) into Trx Tg
mice (n = 16) and Wt mice (n = 16). We observed the sur-
vival rate of TAA-treated mice until 7 days. Moreover, to
estimate the pathophysiological values of livers from Wt
(n = 9) and Tg mice (n = 9), twenty-four hours after TAA
administration, mice were anesthetized by diethylether,
and the livers were removed.
Results
Prevention of acute lethal hepatitis in Tg mice
We used Tg mice to check the protective role of Trx for
acute hepatitis. We subjected both Wt and Tg mice to TAA-
induced acute lethal hepatitis. Survival rate after TAA
administration was significantly higher in Tg mice (n =
16) than in Wt mice (n = 16) (P < 0.01). Twenty four
hours after TAA administration, the AST and ALT levels
were significantly lower in Tg mice than in Wt mice (AST;
7,930 U/ml in Wt mice vs 1,417 U/ml in Tg mice, P < 0.01,
ALT; 10,933 U/ml in Wt mice vs 1,885 U/ml in Tg mice, P
< 0.01). Histological analysis by Hematoxyline & Eosin
staining showed that the destruction of hepatic sinusoid
with massive thrombosis was prominent in wt mice,
whereas it was observed slightly in Tg mice.
Prevention of apoptosis in Tg mice
We found that TAA (100 µg/g) induces apoptosis in the
liver of Wt mice. To determine whether Trx inhibits TAA-
induced apoptosis in the liver, we checked the extent of
apoptotic cells by TUNEL staining and DNA laddering
assay. TUNEL-positive cells around the hepatic central
vein of the livers were smaller in number in Tg mice than
in Wt mice. DNA laddering was striking in TAA-treated liv-
ers of Wt mice, whereas it was hardly detected in TAA-
treated livers of Tg mice.
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Discussion
Trx has not only anti-oxidant effect but also anti-apoptotic
effect. We have previously reported that Trx inhibits brain
ischemic injury via anti-oxidative effect [4]. We have also
reported that Trx inhibited alcohol-induced hepatocyte
cell death [5]. The present study showed that Trx inhibited
TAA-induced apoptosis of hepatocytes via the inhibition
of cytochrome c release from mitochondria. We have pre-
viously reported that, in Jurkat T cells, a thioloxidant,
diamide, induces cytochrome c release, resulting in cas-
pase activation and apoptosis [6]. This process is inhibited
by Trx. In a clinical point of view, it has been reported that
serum Trx level is upregulated in the serum of the patients
with chronic hepatitis [7].
In summary, we present evidence showing that TAA
induces apoptosis of hepatocytes in the liver and that Trx
inhibits TAA-induced apoptotic liver injury. This qualifies
Trx as a promising gene therapy and a drug candidate for
the treatment of acute hepatitis caused by virus infection
and alcohol.
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